Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6PII5
UPID:
HAGHL_HUMAN
Alternative names:
-
Alternative UPACC:
Q6PII5; A6NCC4; D3DU64; Q59FX8; Q96BZ3; Q96NR5; Q96S11; Q9BT45
Background:
Hydroxyacylglutathione hydrolase-like protein, identified by the accession number Q6PII5, plays a crucial role as a hydrolase acting on ester bonds. This enzyme is pivotal in the detoxification process, breaking down harmful substances within cells.
Therapeutic significance:
Understanding the role of Hydroxyacylglutathione hydrolase-like protein could open doors to potential therapeutic strategies. Its involvement in cellular detoxification processes makes it a promising target for developing treatments aimed at enhancing cellular resilience against toxic compounds.